92906-39-3

Usage

Uses

Used in Pharmaceutical Research:
Acetamide, 2-(3-aminophenoxy)-N-phenylis used as a precursor in the synthesis of biologically active molecules for pharmaceutical research. Its unique structure allows for the development of new drugs and organic compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Acetamide, 2-(3-aminophenoxy)-N-phenylserves as a building block for the creation of other organic compounds. Its versatile structure enables the design and synthesis of novel molecules with potential medicinal properties.

Upstream product

• 20916-36-3 (3-nitro-phenoxy)-acetic acid anilide 
• 587-65-5 N-chloroacetyl-aniline 
• 554-84-7 meta-nitrophenol 

Downstream Products

• 105785-64-6 N-(3-Phenylcarbamoylmethoxy-phenyl)-succinamic acid methyl ester 

Relevant academic research and scientific papers

Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.

A series of novel benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters has been prepared. These compounds were tested as inhibitors of rat polymorphonuclear leukocyte 5-lipoxgenase (LO) in vitro and as inhibitors of leukotriene D4 (LTD4) and ovalbumin (OA) induced bronchospasm in the guinea pig (GP) in vivo. In general, inhibitory activity against 5-LO, LTD4, and OA was broadest for benzthiazole-containing analogues (benzthiazole greater than benzimidazole much greater than benzoxazole, benzofuran). The most potent 5-LO inhibitor, 4-[[3-(2-benzthiazolylmethoxy)-phenyl]hydroxyamino]-4-oxobutanoic acid methyl ester (7), had an IC50 of 0.36 microM. Compound 7, however, was inactive vs. OA. The most potent compound in vivo, 4-[[3-[(1-methyl-2-benzimidazolyl)methoxy]phenyl]-amino] -4-oxobutanoic acid methyl ester 4, inhibited both LTD4- and OA-induced bronchospasm by 83% and 60%, respectively, at 50 mg/kg intraduodenally. Compound 4 was studied in the Ames assay employing five strains of bacteria (TA1535, TA1537, TA1538, TA98, and TA100) with and without S-9 rat liver enzyme metabolic activation, and there was no significant number of reversions noted.